end tunnel
beat off-set guidanc consensu
revenu non-gaap ep top consensu
respect top-line beat primarili driven ex-u hcv us hiv
sale despit slight us hcv miss provid guidanc net product sale
lower consensu sg guidanc
in-lin consensu effect tax rate guidanc lower
due tax reform reiter neutral rate updat po
non-gaap ep vs non-gaap ep previous given
hcv sale stabil new hiv launch horizon
us harvoni epclusa sale miss consensu
larg attribut lower patient start price eros share loss result
launch abbv mavyret ex-u epclusa sale howev remain strong beat
hcv guidanc lower consensu
wide anticip investor stabil hcv beyond give us
comfort lower hcv sale estim
hand hiv busi remain solid surpass consensu mainli driven truvada
atripla anticip approv b/f/taf februari continu
strength genvoya odefsey believ gild leadership hiv space
strengthen despit entri gener competit
focu shift away hcv toward pipelin
yescarta post first quarter market impli treat patient
plan expand author center cover elig patient
continu see gradual launch expect multipl trial
car-t therapi progress hematolog solid tumor potenti phase
data bcma car-t multipl myeloma addit expect phase data
filgotinib tnf-refractori rheumatoid arthriti cash
hand believ like continu scout extern opportun
complement pipelin
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
biopharmaceut compani
discov develop commerci
therapi treatment hiv/aid liver
diseas cancer inflamm recent
acquisit kite allow entri car-t
space indic renew focu oncolog
rate neutral believ price
trend patient volum declin
hcv market although hiv franchis
rel healthi hand recent
acquisit kite allow growth
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
price object base multipl estim non-
gaap ep line peer believ multipl justifi given hcv sale
upsid risk price object faster-than-expect growth product
sale less-than-anticip pressur price weaker-than-expect
competit greater faster progress pipelin
downsid risk price object slower-than-expect growth
product sale greater-than-anticip pressur price slower progress
pipelin
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
